Source-grounded facts extracted from Cadrenal Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Quang X. Pham was appointed as interim Chief Financial Officer and interim Principal Accounting Officer at Cadrenal Therapeutics, Inc..
“Effective immediately after Mr. Szot's termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.”
Matthew K. Szot changed role as Chief Financial Officer at Cadrenal Therapeutics, Inc..
“On May 28, 2026, Cadrenal Therapeutics, Inc. (the "Company") and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.”
Cadrenal Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $2.5 million.
“Cadrenal reported a net loss of $2.5 million for the quarter ended March 31, 2026”
Cadrenal Therapeutics, Inc. entered into Inducement Agreement with a holder of Existing Warrants valued at approximately $2.5 million (effective 2026-03-31).
“On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).”
Cadrenal Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $3.0 million for the quarter ending December 31, 2025.
“Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal year ended December 31, 2025.”
Douglas Losordo was terminated as Chief Medical Officer at Cadrenal Therapeutics, Inc..
“On February 4, 2025, the Company terminated its employment relationship with its Chief Medical Officer, Douglas Losordo, on a mutual amicable basis.”
James J. Ferguson III was appointed as Chief Medical Officer at Cadrenal Therapeutics, Inc..
“On February 4, 2025, Cadrenal Therapeutics, Inc. (the “Company”) entered into an employment agreement with James J. Ferguson III (the “Employment Agreement”), effective as of February 5, 2025 (the “Effective Date”), to employ Dr. Ferguson as the Company’s Chief Medical Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.